Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476422 | 0.87 | MTNR1A (0.63) | CNR1SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL7051374 | 0.86 | KMT2A (0.72) | KMT2ASMN1; SMN2GLAMEN1 | |
| SCHEMBL6023589 | 0.83 | KMT2A (0.60) | KMT2AMEN1 | |
| SCHEMBL11083887 | 0.80 | CNR1 (0.57) | CNR1KMT2ASMN1; SMN2GLACNR2 | |
| SCHEMBL6484083 | 0.80 | KMT2A (0.62) | KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6023129 | 0.79 | BCHE (0.54) | KMT2AMEN1 | |
| SCHEMBL63490 | 0.79 | CYP4F2 (0.56) | KMT2ASMN1; SMN2 | |
| SCHEMBL6482686 | 0.78 | HDAC3 (0.64) | KMT2ASMN1; SMN2MEN1MTNR1AMTNR1B | |
| SCHEMBL18183526 | 0.77 | SMN1; SMN2 (0.70) | CNR1SMN1; SMN2CNR2MTNR1AMTNR1B | |
| SCHEMBL6478319 | 0.77 | KMT2A (0.62) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930114-B2 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040138249-A1 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138249-A1 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | PDE7B, PDE2A, PDE5A | CNR1 3290/4885KMT2A 1344/4885SMN1; SMN2 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.